
Opinion|Videos|December 22, 2023
Safety of Available JAK Inhibitors for Treatment of MF
Author(s)Aaron T. Gerds, MD, MS
Aaron Gerds, MD, MS, reviews key safety concerns seen with JAK inhibitors for myelofibrosis treatment.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5







































